Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.

Tandstad, T; Cohn-Cedermark, G; Dahl, O; Stierner, U; Cavallin-Stahl, E; Bremnes, R M; Klepp, O

Tandstad, T; Cohn-Cedermark, G; Dahl, O; Stierner, U; Cavallin-Stahl, E; Bremnes, R M; Klepp, O.

Affiliation

Tandstad T; Department of Oncology, St Olavs University Hospital, Trondheim, Norway. Electronic address: torgrim.tandstad@stolav.no.
Cohn-Cedermark G; Department of Oncology-Pathology, Karolinska Institute and University Hospital, Stockholm, Sweden.
Dahl O; Department of Oncology, Haukeland University Hospital and Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway.
Stierner U; Department of Oncology, Sahlgrenska University Hospital, Gothenburg.
Cavallin-Stahl E; Department of Oncology, Lund University Hospital, Lund, Sweden.
Bremnes RM; Institute of Clinical Medicine, University of Tromsø.
Klepp O; Department of Oncology, Ålesund Hospital, Ålesund, Norway.

Ann Oncol ; 21(9): 1858-1863, 2010 Sep.

Article de En | MEDLINE | ID: mdl-20142410

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du testicule / Protocoles de polychimiothérapie antinéoplasique / Tumeurs embryonnaires et germinales / Tumeurs vasculaires / Récidive tumorale locale Type d'étude: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Humans / Male Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2010 Type de document: Article Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google